Riskpilot← Back to searchSign inGet full accessCAPITOL II AS
ASActiveOrg 990027846Universitetsgata 1, 0164 OsloWholesale of pharmaceutical and medical goods · NACE 4646Est. 20060 employees
Revenue 2024
NOK 0
EBITDA margin
—
-6% vs 2023
Equity ratio
99.8%
Financial strength
Net profit 2024
NOK 3,7M
+57% vs 2023
| Revenue | NOK 0 | — |
| EBITDA | NOK -346K | -6% |
| Net profit | NOK 3,7M | +57% |
| Total assets | NOK 28,6M | +0% |
| Equity | NOK 28,5M | +2% |
| Employees | 0 | — |
Legal name
CAPITOL II AS
Org number
990027846
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
3. juli 2006
Share capital
NOK 100 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Selskapet driver investeringsvirksomhet, herunder investeringer i aksjer, obligasjoner, selskapsandeler, verdipapirer, fast eiendom, utlånsvirksomhet eller annen virksomhet, selv eller gjennom hel- eller deleide selskaper.
Address
Universitetsgata 1, 0164 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | −0 | −0 | −0 | −24 | −30 |
| EBITDA | −131 | −410 | −256 | −328 | −346 |
| Depreciation & amort. | −0 | −0 | −0 | −139 | −139 |
| EBIT | −131 | −410 | −256 | −467 | −485 |
| Net financials | 1 437 | 1 912 | 3 002 | 3 276 | 4 198 |
| Profit before tax | 1 306 | 1 502 | 2 745 | 2 809 | 3 713 |
| Tax | −0 | −0 | −0 | 439 | −0 |
| Net profit | 1 306 | 1 502 | 2 745 | 2 370 | 3 713 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 28 095 | 28 592 | 29 558 | 28 525 | 28 583 |
| Equity | 28 089 | 28 591 | 28 637 | 28 006 | 28 519 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 6 | 1 | 921 | 518 | 64 |
| Total debt | 6 | 1 | 921 | 518 | 64 |
EBITDA margin
-34591300.0%
This company
15.8%
Market median
-218932378% vs market
20202024
Equity ratio
99.8%
This company
38.2%
Market median
+161% vs market
20202024
Return on equity
13.0%
This company
18.4%
Market median
+29% vs market
20202024
Net profit margin
371262000.0%
This company
8.1%
Market median
+4583481381% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2006 | |
| Chairman | 2025 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 12.4% | 12.4% | 2024 | |
| Individual | 12.4% | 12.4% | 2022 | |
| Individual | 12.4% | 12.4% | 2024 | |
| Individual | 12.4% | 12.4% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
CAPITOL II AS (this company)
ENDOMED ASBoard members of CAPITOL II AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Sverre Frich | Chairman | 0 companies |
| Karen Margrethe Bugge | Chairman | 0 companies |